3-(4-Cyclopropyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-2-methyl-acrylic acid ethyl ester 在
钯 作用下,
以
乙醇 为溶剂,
以to give the title compound in 3.1 g (53%)的产率得到3-(4-cyclopropyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-2-methyl-propionic acid ethyl ester
参考文献:
名称:
ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
申请人:Edwards Louise
公开号:US20080045571A1
公开(公告)日:2008-02-21
The present invention relates to new compounds of formula I,
to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
[EN] ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS<br/>[FR] COMPOSES HETEROPOLYCYCLIQUES SUPPLEMENTAIRES ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR METABOTROPIQUE DU GLUTAMATE
申请人:ASTRAZENECA AB
公开号:WO2006014185A1
公开(公告)日:2006-02-09
The present invention relates to new compounds of formula (I), to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
申请人:Edwards Louise
公开号:US20050272779A1
公开(公告)日:2005-12-08
The present invention relates to new compounds of formula I,
to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.